Unique ID issued by UMIN | UMIN000049936 |
---|---|
Receipt number | R000056873 |
Scientific Title | Efficacy and Safety of Nivolumab+Ipilimumab or Pembrolizumab for Patients with Untreated Advanced or Recurrent Non-small Cell Lung Cancer; A Multicenter Retrospective Observational Study |
Date of disclosure of the study information | 2022/12/29 |
Last modified on | 2023/03/03 13:21:46 |
Efficacy and Safety of Nivolumab+Ipilimumab or Pembrolizumab for Patients with Untreated Advanced or Recurrent Non-small Cell Lung Cancer; A Multicenter Retrospective Observational Study
Efficacy and Safety of Nivolumab+Ipilimumab or Pembrolizumab for Patients with Untreated Advanced or Recurrent Non-small Cell Lung Cancer; A Multicenter Retrospective Observational Study
Efficacy and Safety of Nivolumab+Ipilimumab or Pembrolizumab for Patients with Untreated Advanced or Recurrent Non-small Cell Lung Cancer; A Multicenter Retrospective Observational Study
Efficacy and Safety of Nivolumab+Ipilimumab or Pembrolizumab for Patients with Untreated Advanced or Recurrent Non-small Cell Lung Cancer; A Multicenter Retrospective Observational Study
Japan |
Non-small cell lung cancer
Pneumology |
Malignancy
NO
To investigate the efficacy and safety, and those risk factors of CM227 and CM9LA regimens as first-line therapy for patients with advanced or recurrent non-small cell lung cancer. To compare to those of KN189 regimen
Safety,Efficacy
The efficacy (objective response rate, progression-free survival,and overall survival) and safety (adverse events, serious adverse events,and treatment-related death) of CM227 and CM9LA regimens
Observational
18 | years-old | <= |
120 | years-old | >= |
Male and Female
1) Patients with non-small cell lung cancer who have clinical stage III, IV or relapsed after radical treatment with surgery or radiotherapy according to the TNM classification, 8th edition
2) Patients who started CM227 or CM9LA or KN189 regimens as first-line therapy between December 1, 2018 and May 31, 2022
Nothing
450
1st name | Takayuki |
Middle name | |
Last name | Shiroyama |
Graduate School of Medicine, Osaka University
Department of Respiratory Medicine and Clinical Immunology
565-0871
2-2, Yamadaoka, Suita-city, Osaka
06-6879-3831
shiroyamat@imed3.med.osaka-u.ac.jp
1st name | Kinnosuke |
Middle name | |
Last name | Matsumoto |
Graduate School of Medicine, Osaka University
Department of Respiratory Medicine and Clinical Immunology
565-0871
2-2, Yamadaoka, Suita-city, Osaka
06-6879-3831
m.kinnosuke@gmail.com
Graduate School of Medicine, Osaka University
Graduate School of Medicine, Osaka University
Self funding
Graduate School of Medicine, Osaka University
2-2, Yamadaoka, Suita-city, Osaka
565-0871
m.kinnosuke@gmail.com
NO
2022 | Year | 12 | Month | 29 | Day |
Unpublished
Open public recruiting
2022 | Year | 12 | Month | 06 | Day |
2023 | Year | 03 | Month | 02 | Day |
2023 | Year | 03 | Month | 02 | Day |
2023 | Year | 12 | Month | 31 | Day |
Nothing
2022 | Year | 12 | Month | 28 | Day |
2023 | Year | 03 | Month | 03 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000056873
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |